Treatment
Naxitamab clinical trials
We’re tracking 9 recruiting studies that include Naxitamab, each written for real people, not researchers, below.
Recruiting studies
- NCT06013618RecruitingPhase 2
Naxitamab for high-risk or relapsed neuroblastoma in children
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
Guangzhou, GuangdongAges 1 year+ - NCT05489887RecruitingPhase 2
Naxitamab with frontline chemotherapy for high-risk neuroblastoma
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
Birmingham, AlabamaAges 1–21 - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT07027748RecruitingPhase 1
Testing a longer treatment of three drugs for neuroblastoma
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Boston, MassachusettsAges 1–30 - NCT05968768RecruitingPhase 2
Naxitamab trial for children with treatment-resistant Ewing sarcoma
This Phase 2 trial studies naxitamab (a targeted antibody) in children and young adults whose Ewing sarcoma has come back or kept growing despite prior treatment. You may be eligible if the tumor shows a target called GD2 and if your heart, lungs, and past treatment recovery meet safety requirements.
Warsaw, MazowianAges 2–21 - NCT06540963RecruitingPhase 2
Tipifarnib and naxitamab for relapsed or refractory neuroblastoma
This trial tests a combination of two drugs (tipifarnib and naxitamab) for children and young adults with neuroblastoma that has come back or hasn't responded to standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
Little Rock, ArkansasAges 1–21 - NCT06574698Recruiting
Adding Naxitamb to high-risk neuroblastoma treatment
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
Guanzhou, GuangdongAges 1–21 - NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT05754684RecruitingPhase 2
Immunotherapy with donor NK cells for relapsed neuroblastoma
This trial studies a “quadruple immunotherapy” treatment using donor immune cells (NK cells) to fight neuroblastoma that has come back or did not respond to prior therapy. It may help by boosting the body’s immune attack, but only certain children meet the safety and donor requirements.
Hong KongAges Up to 18 years
What Naxitamab is being studied for
Conditions with recruiting Naxitamab studies.
Common questions
- Are there clinical trials studying Naxitamab?
- Yes. Clin2 currently lists 9 recruiting studies that include Naxitamab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Naxitamab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Naxitamab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Naxitamab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.